SanBio Company Limited announced that at a Board of Directors meeting held September 14, 2020 it has resolved to appoint Akihiro Tsujimura current Senior Managing Director of SanBio Co. Ltd. and CEO of SanBio Inc. to the position of Executive Vice President and Chief Operating Officer (COO), effective September 15, 2020 (September 14, 2020, US time) for the development of the Group as a whole. Mr. Tsujimura accumulated diverse experience in corporate management while working at Nichimen Corp. (current Sojitsu Corp.), through his involvement in various operations ranging from the establishment and management of overseas businesses to corporate turnarounds in Japan. At Santen Pharmaceutical Co. Ltd., he gained a wealth of experience in pharmaceutical business operations, including business development, M&A, and overseas expansion. The SanBio Group expects Mr. Tsujimura to draw on his experience and track record in corporate management to make further contributions to the Group's global expansion. He will maintain his position of CEO at SanBio Inc., the Company's U.S. subsidiary. Currently, the SanBio Group is working toward filing for manufacture and marketing approval of SB623 as a regenerative medicine product for the treatment of chronic motor deficit from traumatic brain injury (TBI) in Japan by the end of the fiscal year ending January 2021 (February 2020­ January 2021). As the new Vice President and COO of the Company, Mr. Tsujimura will oversee the entire operation of the Group, including making necessary preparations to launch SB623 as a therapeutic drug for the treatment of chronic effects resulting from TBI in Japan and in other countries thereafter (i.e., global development of the product), as well as preparations to resume clinical trials in the ischemic stroke program. Under his leadership, the company will aim to maximize the value of SB623 and continue considering various development options, including in-house development and entering partnerships.